A Mab A Case Study In Bioprocess Development _top_ 〈Premium〉
The A-Mab Case Study is a landmark document in the biopharmaceutical industry, serving as a comprehensive blueprint for applying Quality by Design (QbD) principles to monoclonal antibody (mAb) development. Published in 2009 by the CMC Biotech Working Group, it remains a primary educational resource for understanding how to integrate regulatory guidelines (ICH Q8, Q9, and Q10) into real-world manufacturing. Key Takeaways & Core Concepts
Formulation
Root Cause Analysis: Lowering the pH during harvest. As the culture ages, CO2 builds up, lowering pH to 6.7. Mab-X has a unique hydrophobic patch in the Fc region that is prone to unfolding at pH <6.8. A Mab A Case Study In Bioprocess Development
10. Scale-up, Tech Transfer, and Manufacturing Strategies
- Scale-up roadmap: bench → pilot (50–500 L) → clinical (200–2000 L) → commercial (2000–20,000 L) decisions.
- Tech transfer documentation: batch records, process flow diagrams, critical SOPs, validation protocols.
- Facility options: CDMO vs in-house; single-use vs stainless steel; disposables benefits and limitations (extractables, footprint).
- Supply chain considerations: raw material quality, resin lifetime, cold chain for intermediates.
The Intervention: The development team shifts from a traditional batch process to a fed-batch process with a chemically defined, animal-component-free medium. Using Design of Experiments (DoE), they optimize the feed strategy: The A-Mab Case Study is a landmark document